Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0N3EJ
|
||||
| Former ID |
DCL000958
|
||||
| Drug Name |
RGH-896
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetic peripheral neuropathic pain [ICD9: 250.6, 338,780; ICD10:E10.4, E11.4, E13.4, R52, G89] | Phase 2 | [536374] | ||
| Therapeutic Class |
Analgesics
|
||||
| Company |
Gedeon Richter
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C36H60N2O7P+
|
||||
| Canonical SMILES |
CCCCCCCCCCCCCCCCCCNC(=O)OCC1CCC(O1)COP(=O)(O)OCC[N+]2=C<br />C=CC3=CC=CC=C32
|
||||
| InChI |
1S/C36H59N2O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-26-37-36(39)42-30-33-24-25-34(45-33)31-44-46(40,41)43-29-28-38-27-20-22-32-21-17-18-23-35(32)38/h17-18,20-23,27,33-34H,2-16,19,24-26,28-31H2,1H3,(H-,37,39,40,41)/p+1/t33-,34+/m0/s1
|
||||
| InChIKey |
OLDMQSKCCHULOB-SZAHLOSFSA-O
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Glutamate [NMDA] receptor subunit epsilon 2 | Target Info | Antagonist | [536374] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| Alcoholism | |||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| Reelin signaling pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.